Sanofi Price to Free Cash Flow Ratio 2012-2025 | SNY
Historical price to free cash flow ratio values for Sanofi (SNY) since 2012.
| Sanofi Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-03-04 | 46.22 | 14.61 | |
| 2025-09-30 | 47.20 | $3.16 | 14.91 |
| 2025-06-30 | 48.31 | $4.30 | 11.23 |
| 2025-03-31 | 53.11 | $4.06 | 13.09 |
| 2024-12-31 | 46.18 | $3.16 | 14.59 |
| 2024-09-30 | 55.18 | $3.55 | 15.53 |
| 2024-06-30 | 46.46 | $2.22 | 20.97 |
| 2024-03-31 | 44.65 | $3.55 | 12.57 |
| 2023-12-31 | 45.68 | $3.55 | 12.86 |
| 2023-09-30 | 49.28 | $4.11 | 11.98 |
| 2023-06-30 | 49.51 | $5.51 | 8.98 |
| 2023-03-31 | 48.11 | $4.11 | 11.70 |
| 2022-12-31 | 42.81 | $4.11 | 10.41 |
| 2022-09-30 | 33.61 | 0 | 0.00 |
| 2022-06-30 | 44.23 | 0 | 0.00 |
| 2022-03-31 | 43.67 | 0 | 0.00 |
| 2021-09-30 | 41.00 | 0 | 0.00 |
| 2021-03-31 | 40.54 | 0 | 0.00 |
| 2020-09-30 | 41.12 | 0 | 0.00 |
| 2020-03-31 | 34.55 | 0 | 0.00 |
| 2019-09-30 | 36.61 | $2.66 | 13.77 |
| 2019-03-31 | 33.59 | $1.78 | 18.82 |
| 2018-03-31 | 28.94 | $2.66 | 10.89 |
| 2017-12-31 | 31.05 | $2.66 | 11.68 |
| 2017-09-30 | 35.95 | $2.55 | 14.12 |
| 2017-06-30 | 34.59 | $2.78 | 12.44 |
| 2017-03-31 | 31.64 | $2.55 | 12.43 |
| 2016-12-31 | 28.27 | $2.55 | 11.10 |
| 2016-09-30 | 26.70 | $-1.09 | 0.00 |
| 2016-06-30 | 29.26 | $-0.44 | 0.00 |
| 2016-03-31 | 26.94 | $-0.78 | 0.00 |
| 2015-09-30 | 31.85 | $-1.76 | 0.00 |
| 2015-06-30 | 33.23 | $1.09 | 30.62 |
| 2014-06-30 | 34.52 | $1.08 | 31.88 |
| 2013-06-30 | 32.27 | $4.91 | 6.57 |
| 2012-06-30 | 22.88 | $4.15 | 5.51 |
| 2012-03-31 | 22.37 | $4.13 | 5.41 |
| 2011-12-31 | 21.10 | $4.13 | 5.10 |
| 2011-09-30 | 18.94 | $4.23 | 4.48 |
| 2011-06-30 | 23.19 | $4.24 | 5.47 |
| 2011-03-31 | 19.40 | $4.23 | 4.58 |
| 2010-12-31 | 17.75 | $4.23 | 4.19 |
| 2010-09-30 | 18.31 | $3.64 | 5.04 |
| 2010-06-30 | 16.56 | $3.51 | 4.72 |
| 2010-03-31 | 19.51 | $3.64 | 5.37 |
| 2009-12-31 | 20.51 | $3.64 | 5.64 |
| 2009-09-30 | 19.30 | $4.31 | 4.47 |
| 2009-06-30 | 15.40 | $4.66 | 3.30 |
| 2009-03-31 | 13.84 | $4.31 | 3.21 |
| 2008-12-31 | 15.93 | $4.31 | 3.69 |
| 2008-09-30 | 16.29 | $2.99 | 5.45 |
| 2008-06-30 | 16.47 | $3.19 | 5.16 |
| 2008-03-31 | 17.87 | $2.99 | 5.98 |
| 2007-12-31 | 21.68 | $2.99 | 7.25 |
| 2007-09-30 | 20.20 | $2.95 | 6.85 |
| 2007-06-30 | 19.17 | $2.62 | 7.33 |
| 2007-03-31 | 20.22 | $2.95 | 6.86 |
| 2006-12-31 | 21.46 | $2.95 | 7.28 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $112.219B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |